{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:08:49Z","timestamp":1787065729667,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","issue":"34","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1137582"],"award-info":[{"award-number":["1137582"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.vaccine.2021.07.013","type":"journal-article","created":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T00:23:29Z","timestamp":1625876609000},"page":"4784-4787","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination \u2013 A risk\u2013benefit analysis for people\u00a0&lt;\u00a060\u00a0years in Australia"],"prefix":"10.1016","volume":"39","author":[{"given":"Chandini Raina","family":"MacIntyre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8849-2892","authenticated-orcid":false,"given":"Benjamin","family":"Veness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6005-9683","authenticated-orcid":false,"given":"Noor","family":"Bari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.07.013_b0005","unstructured":"British Society for Haematology. Guidance from the Expert Haematology Panel (EHP) on Covid-19 Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT). United Kingdom: British Society of Haematology 2021 May 28 2021."},{"key":"10.1016\/j.vaccine.2021.07.013_b0010","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.vaccine.2021.07.013_b0015","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1128\/JVI.02819-06","article-title":"Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver","volume":"81","author":"Stone","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.07.013_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102662","article-title":"Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection","volume":"121","author":"McGonagle","year":"2021","journal-title":"J Autoimmun"},{"key":"10.1016\/j.vaccine.2021.07.013_b0025","article-title":"Vaccine-Induced Covid-19 Mimicry\u201d Syndrome: Splice reactions within the SARS-CoV-2 Spike open reading frame result in Spike protein variants that may cause thromboembolic events in patients immunized with vector-based vaccines","author":"Eric","year":"2021","journal-title":"Res Square"},{"key":"10.1016\/j.vaccine.2021.07.013_b0030","unstructured":"Australian Department of Health. Coronavirus (COVID-19) current situation and case numbers Canberra: Australian Government 2020 [Available from: https:\/\/www.health.gov.au\/news\/health-alerts\/novel-coronavirus-2019-ncov-health-alert\/coronavirus-covid-19-current-situation-and-case-numbers."},{"issue":"12","key":"10.1016\/j.vaccine.2021.07.013_b0035","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s10654-020-00698-1","article-title":"Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications","volume":"35","author":"Levin","year":"2020","journal-title":"Eur J Epidemiol"},{"issue":"9289","key":"10.1016\/j.vaccine.2021.07.013_b0040","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S0140-6736(01)06346-2","article-title":"Effect of rotavirus vaccination programme on trends in admission of infants to hospital for intussusception","volume":"358","author":"Simonsen","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.07.013_b0045","unstructured":"Centers for Disease Control. Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep. 1999;48(43):1007."},{"key":"10.1016\/j.vaccine.2021.07.013_b0050","unstructured":"Statistics. ABo. National, state and territory population. In: Statistics ABo, editor. Canberra: Australian Government; 2020."},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2021.07.013_b0055","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ans.16564","article-title":"Prevalence of asymptomatic SARS-CoV-2 infection in elective surgical patients in Australia: a prospective surveillance study","volume":"91","author":"Coatsworth","year":"2021","journal-title":"ANZ J Surg."},{"key":"10.1016\/j.vaccine.2021.07.013_b0060","doi-asserted-by":"crossref","unstructured":"Stout RL, Rigatti SJ. Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020. JAMA Network Open. 2021;4(3):e211552-e.","DOI":"10.1001\/jamanetworkopen.2021.1552"},{"issue":"5","key":"10.1016\/j.vaccine.2021.07.013_b0065","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/M20-3012","article-title":"Prevalence of Asymptomatic SARS-CoV-2 Infection","volume":"173","author":"Oran","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2021.07.013_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.07.013_b0075","unstructured":".Australian Department of Health and Ageing. Preliminary advice from ATAGI on general principles for the COVID-19 vaccination program. In: Immunisation ATAGo, editor. Canberra: Australian Government; 2020. https:\/\/www.health.gov.au\/news\/preliminary-advice-from-atagi-on-general-principles-for-the-covid-19-vaccination-program."},{"key":"10.1016\/j.vaccine.2021.07.013_b0080","unstructured":"Australian Government. ATAGI statement on revised recommendations on the use of COVID-19 Vaccine AstraZeneca, 17 June 2021 Canberra2021 [Available from: https:\/\/www.health.gov.au\/news\/atagi-statement-on-revised-recommendations-on-the-use-of-covid-19-vaccine-astrazeneca-17-june-2021."},{"key":"10.1016\/j.vaccine.2021.07.013_b0085","article-title":"A prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia following coronavirus-19 Vaccination","author":"Andreas","year":"2021","journal-title":"Res Square."},{"key":"10.1016\/j.vaccine.2021.07.013_b0090","unstructured":"Government of the United Kingdom. Coronavirus vaccine - weekly summary of Yellow Card reporting 2021 [Available from: https:\/\/www.gov.uk\/government\/publications\/coronavirus-covid-19-vaccine-adverse-reactions\/coronavirus-vaccine-summary-of-yellow-card-reporting."},{"key":"10.1016\/j.vaccine.2021.07.013_b0095","article-title":"Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study","volume":"373","author":"Potteg\u00e5rd","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.vaccine.2021.07.013_b0100","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7205\/MILMED-D-12-00226","article-title":"Myopericarditis and pericarditis in the deployed military member: a retrospective series","volume":"178","author":"Lin","year":"2013","journal-title":"Mil Med"},{"issue":"1","key":"10.1016\/j.vaccine.2021.07.013_b0105","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jacc.2004.05.004","article-title":"Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination","volume":"44","author":"Eckart","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.vaccine.2021.07.013_b0110","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/jmv.24285","article-title":"Vaccine associated paralytic poliomyelitis cases from children presenting with acute flaccid paralysis in Uganda","volume":"87","author":"Nanteza","year":"2015","journal-title":"J Med Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2021.07.013_b0115","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1467-842X.2001.tb00648.x","article-title":"Cost-effectiveness analysis of changing from live oral poliovirus vaccine to inactivated poliovirus vaccine in Australia","volume":"25","author":"Tucker","year":"2001","journal-title":"Aust N Z J Public Health."},{"key":"10.1016\/j.vaccine.2021.07.013_b0120","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant","author":"Madhi","year":"2021","journal-title":"N Engl J Med"},{"issue":"6537","key":"10.1016\/j.vaccine.2021.07.013_b0125","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1126\/science.372.6537.14","article-title":"Side effect worry grows for AstraZeneca vaccine","volume":"372","author":"Vogel","year":"2021","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.vaccine.2021.07.013_b0130","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11673-018-9841-1","article-title":"Raising rates of childhood vaccination: the trade-off between coercion and trust","volume":"15","author":"Haire","year":"2018","journal-title":"J Bioethical Inquiry"},{"key":"10.1016\/j.vaccine.2021.07.013_b0135","article-title":"Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW","author":"MacIntyre","year":"2021","journal-title":"Australia Vaccine"},{"key":"10.1016\/j.vaccine.2021.07.013_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(21)00079-7","article-title":"The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation","author":"Sandmann","year":"2021","journal-title":"Lancet Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21008720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21008720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:58:55Z","timestamp":1759402735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21008720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":28,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0264410X21008720"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.07.013","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination \u2013 A risk\u2013benefit analysis for people\u00a0<\u00a060\u00a0years in Australia","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}